pulmoПульмонологияPULMONOLOGIYA0869-01892541-9617Scientific and Practical Journal “PULMONOLOGIYA” LLC10.18093/0869-0189-2011-0-4-126-132pulmo-369Research ArticleОБЗОРЫREVIEWОстеопороз у больных муковисцидозом: новая проблема и нерешенные вопросыOsteoporosis in cystic fibrosis patients: a new problem and unresolved issuesБарановаИ. А.BaranovaI. A.

д. м. н., проф. кафедры госпитальной терапии педиатрического факультета

117997, Москва, ул. Островитянова, 1. Тел.: (495) 965-45-20.

КрасовскийС. А.KrasovskyS. A.

научный сотрудник 

105077, Москва, ул. 11-я Парковая, 32, корп. 4. Тел.: 8-926-273-76-34.

АмелинаЕ. Л.AmelinaE. L.

к. м. н., зав. лабораторией муковисцидоза 

105077, Москва, ул. 11-я Парковая, 32, корп. 4. Тел.: 8-926-205-03-91.

ГОУ ВПО "РНИМУ им. Н.И.Пирогова" Росздрава; РГМУRussian FederationФГУ "НИИ пульмонологии" ФМБА РоссииRussian Federation20112808201104126132Copyright © Баранова И.А., Красовский С.А., Амелина Е.Л., 20112011Баранова И.А., Красовский С.А., Амелина Е.Л.Baranova I.A., Krasovsky S.A., Amelina E.L.Данная работа распространяется под лицензией Creative Commons Attribution 4.0.This work is licensed under a Creative Commons Attribution 4.0 License.https://journal.pulmonology.ru/pulm/article/view/369

Остеопороз у больных муковисцидозом: новая проблема и нерешенные вопросы.

Osteoporosis in cystic fibrosis patients: a new problem and unresolved issues.

муковисцидозостеопорозминеральная плотность костипереломыcystic fibrosisosteoporosisbone mineral densityfracturesReferencesКапранов Н.И., Каширская Н.Ю. (ред.). Муковисцидоз. Современные достижения и актуальные проблемы: Метод. рекомендации. 3-е изд. М.: ООО "4ТЕ Арт"; 2008.Капранов Н.И., Каширская Н.Ю. (ред.). Муковисцидоз. Современные достижения и актуальные проблемы: Метод. рекомендации. 3-е изд. М.: ООО "4ТЕ Арт"; 2008.Кусова З.А., Каширская Н.Ю., Капранов Н.И. Особенности массового скрининга новорожденных на муковисцидоз. Рус. мед. журн. 2010; 5: 265–270.Кусова З.А., Каширская Н.Ю., Капранов Н.И. Особенности массового скрининга новорожденных на муковисцидоз. Рус. мед. журн. 2010; 5: 265–270.Cystic Fibrosis Foundation, patient registry 2008. Annual report Cystic Fibrosis Foundation. Bethesda, Md, USA, 2009.Cystic Fibrosis Foundation, patient registry 2008. Annual report Cystic Fibrosis Foundation. Bethesda, Md, USA, 2009.King S.J., Topliss D.J., Kotsimbos T. et al. Reduced bone density in cystic fibrosis: DeltaF508 mutation is an independent risk factor. Eur. Respir. J. 2005; 25: 54–61.King S.J., Topliss D.J., Kotsimbos T. et al. Reduced bone density in cystic fibrosis: DeltaF508 mutation is an independent risk factor. Eur. Respir. J. 2005; 25: 54–61.Grey A.B., Ames R.W., Matthews R.D. et al. Bone mineral density and body composition in adult patients with cystic fibrosis. Thorax 1993; 48: 589–593.Grey A.B., Ames R.W., Matthews R.D. et al. Bone mineral density and body composition in adult patients with cystic fibrosis. Thorax 1993; 48: 589–593.Elkin S.L., Fairney A., Burnett S. et al. Vertebral deformities and low bone mineral density in adults with cystic fibrosis: a cross-sectional study. Osteoporos Int 2001; 12: 366–372.Elkin S.L., Fairney A., Burnett S. et al. Vertebral deformities and low bone mineral density in adults with cystic fibrosis: a cross-sectional study. Osteoporos Int 2001; 12: 366–372.Stephenson A., Jamal S., Dowdell T. et al. Prevalence of vertebral fractures in adults with cystic fibrosis and their relationship to bone mineral density. Chest 2006; 130: 539–544.Stephenson A., Jamal S., Dowdell T. et al. Prevalence of vertebral fractures in adults with cystic fibrosis and their relationship to bone mineral density. Chest 2006; 130: 539–544.Aris R.M., Renner J.B., Winders A.D. et al. Increased rate of fractures and severe kyphosis: sequelae of living into adulthood with cystic fibrosis. Ann. Intern. Med. 1998; 128 (3): 186–193.Aris R.M., Renner J.B., Winders A.D. et al. Increased rate of fractures and severe kyphosis: sequelae of living into adulthood with cystic fibrosis. Ann. Intern. Med. 1998; 128 (3): 186–193.Paccou J., Zeboulon N., Combescure C. et al. The prevalence of osteoporosis, osteopenia, and fractures: a systematic literature review with meta-analysis. Calcif. Tissue Int. 2010; 86: 1–7.Paccou J., Zeboulon N., Combescure C. et al. The prevalence of osteoporosis, osteopenia, and fractures: a systematic literature review with meta-analysis. Calcif. Tissue Int. 2010; 86: 1–7.Aringer M., Kiener H.P., Koeller M.D. et al. High turnover bone disease following lung transplantation. Bone 1998; 23 (5): 485–488.Aringer M., Kiener H.P., Koeller M.D. et al. High turnover bone disease following lung transplantation. Bone 1998; 23 (5): 485–488.Shane E., Papadopoulos A., Staron R.B. et al. Bone loss and fracture after lung transplantation. Transplantation 1999; 68 (2): 220–227.Shane E., Papadopoulos A., Staron R.B. et al. Bone loss and fracture after lung transplantation. Transplantation 1999; 68 (2): 220–227.Official position of the International Society for Clinical Densitometry. c Copyright ISCD, October 2007, Supersedes all prior "Official Position" publications.Official position of the International Society for Clinical Densitometry. c Copyright ISCD, October 2007, Supersedes all prior "Official Position" publications.Report of the UK Cystic Fibrosis Trust Bone Mineralisation Working Group. Bone mineralisation in cystic fibrosis. February 2007. Cystic Fibrosis Trust.Report of the UK Cystic Fibrosis Trust Bone Mineralisation Working Group. Bone mineralisation in cystic fibrosis. February 2007. Cystic Fibrosis Trust.Aris R.M., Merkel P.A., Bachrach L.K. et al. Consensus statement: Guide to bone health and disease in cystic fibrosis. J. Clin. Endocrinol. 2005; 90 (3):1888–1896.Aris R.M., Merkel P.A., Bachrach L.K. et al. Consensus statement: Guide to bone health and disease in cystic fibrosis. J. Clin. Endocrinol. 2005; 90 (3):1888–1896.Haworth C.S., Webb A.K., Egan J.J. et al. Bone histomorphometry in adult patients with cystic fibrosis. Chest 2000; 118: 434–439.Haworth C.S., Webb A.K., Egan J.J. et al. Bone histomorphometry in adult patients with cystic fibrosis. Chest 2000; 118: 434–439.Elkin S.L., Vedi S., Bord S. et al. Histomorphometric analysis of bone biopsies from the iliac crest of adults with cystic fibrosis. Am. J. Respir. Crit. Care Med. 2002; 166: 1470–1474.Elkin S.L., Vedi S., Bord S. et al. Histomorphometric analysis of bone biopsies from the iliac crest of adults with cystic fibrosis. Am. J. Respir. Crit. Care Med. 2002; 166: 1470–1474.Mischler E.H., Chesney P.J., Chesney R.W. et al. Demineralization in cystic fibrosis detected by direct photon absorptiometry. Am. J. Dis. Child. 1979; 133: 632–635.Mischler E.H., Chesney P.J., Chesney R.W. et al. Demineralization in cystic fibrosis detected by direct photon absorptiometry. Am. J. Dis. Child. 1979; 133: 632–635.Hahn T.J., Squires A.E., Halstead L.R. et al. Reduced serum 25-hydroxyvitamin D concentration and disordered mineral metabolism in patients with cystic fibrosis. J. Pediatr. 1979; 94: 38–42.Hahn T.J., Squires A.E., Halstead L.R. et al. Reduced serum 25-hydroxyvitamin D concentration and disordered mineral metabolism in patients with cystic fibrosis. J. Pediatr. 1979; 94: 38–42.Paccou J., Zeboulon N., Combescure C. et al. The prevalence of osteoporosis, osteopenia, and fractures: a systematic literature review with meta-analysis. Calcif. Tissue Int. 2010; 86: 1–7.Paccou J., Zeboulon N., Combescure C. et al. The prevalence of osteoporosis, osteopenia, and fractures: a systematic literature review with meta-analysis. Calcif. Tissue Int. 2010; 86: 1–7.Haworth C.S., Selby P.L., Webb A.K. et al. Low bone mineral density in adults with cystic fibrosis. Thorax 1999; 54: 961–967.Haworth C.S., Selby P.L., Webb A.K. et al. Low bone mineral density in adults with cystic fibrosis. Thorax 1999; 54: 961–967.Buntain H.M., Schluter P.J., Bell S.C. et al. Controlled longitudinal study of bone mass accrual in children and adolescents with cystic fibrosis. Thorax 2006; 61: 146–154.Buntain H.M., Schluter P.J., Bell S.C. et al. Controlled longitudinal study of bone mass accrual in children and adolescents with cystic fibrosis. Thorax 2006; 61: 146–154.Haworth C.S., Selby P.L., Horrrocks A.W. et al. A prospective study of change in bone mineral density over one year in adults with cystic fibrosis. Thorax 2002; 57: 719–723.Haworth C.S., Selby P.L., Horrrocks A.W. et al. A prospective study of change in bone mineral density over one year in adults with cystic fibrosis. Thorax 2002; 57: 719–723.Bhudhikanok G.S., Wang M.)C., Marcus R. et al. Bone acquisition and loss in children and adults with cystic fibrosis: a longitudinal study. J. Pediatr. 1998; 133: 18–27.Bhudhikanok G.S., Wang M.)C., Marcus R. et al. Bone acquisition and loss in children and adults with cystic fibrosis: a longitudinal study. J. Pediatr. 1998; 133: 18–27.Dif F., Marty C., Baudoin C. et al. Severe osteopenia in CFTR-null mice. Bone 2004; 35: 595–603.Dif F., Marty C., Baudoin C. et al. Severe osteopenia in CFTR-null mice. Bone 2004; 35: 595–603.Haston C.K., Li W., Li A. et al. Persistent osteopenia in adult cystic fibrosis transmembrane conductance regulator-deficient mice. Am. J. Respir. Crit. Care Med. 2008; 177: 309–315.Haston C.K., Li W., Li A. et al. Persistent osteopenia in adult cystic fibrosis transmembrane conductance regulator-deficient mice. Am. J. Respir. Crit. Care Med. 2008; 177: 309–315.King S.L., Topliss D.J., Kotsimbos T. et al. Reduced bone density in cystic fibrosis: ΔF508 mutation is an independent risk factor. Eur. Respir. J. 2005; 25: 54–61.King S.L., Topliss D.J., Kotsimbos T. et al. Reduced bone density in cystic fibrosis: ΔF508 mutation is an independent risk factor. Eur. Respir. J. 2005; 25: 54–61.Buntain H.M., Greer R.M., Schluter P.J. et al. Bone mineral density in Australian children, adolescents and adults with cystic fibrosis: a controlled cross sectional study. Thorax 2004; 59: 149–155.Buntain H.M., Greer R.M., Schluter P.J. et al. Bone mineral density in Australian children, adolescents and adults with cystic fibrosis: a controlled cross sectional study. Thorax 2004; 59: 149–155.Aris R.M., Guise T.A. Cystic fibrosis and bone disease: are we missing a genetic link? Eur. Respir. J. 2005; 25 (1): 9–11.Aris R.M., Guise T.A. Cystic fibrosis and bone disease: are we missing a genetic link? Eur. Respir. J. 2005; 25 (1): 9–11.Shead E.F., Haworth C.S., Condliffe A.M. et al. Cystic fibrosis transmembrane conductance regulator (CFTR) is expressed in human bone. Thorax 2007; 62: 650–651.Shead E.F., Haworth C.S., Condliffe A.M. et al. Cystic fibrosis transmembrane conductance regulator (CFTR) is expressed in human bone. Thorax 2007; 62: 650–651.Le Heron L., Guillaume C., Velard F. et al. Cystic fibrosis transmembrane conductance regulator (CFTR) regulates the production of osteoprotegerin (OPG) and prostaglandin (PG) E2 in human bone. J. Cyst. Fibros. 2010; 9: 69–72.Le Heron L., Guillaume C., Velard F. et al. Cystic fibrosis transmembrane conductance regulator (CFTR) regulates the production of osteoprotegerin (OPG) and prostaglandin (PG) E2 in human bone. J. Cyst. Fibros. 2010; 9: 69–72.Lacativa P.G.S., de Farias V.L.F. Osteoporosis and inflammation. Arq. Bras. Endocrinol. 2010: 54 (2): 123–132.Lacativa P.G.S., de Farias V.L.F. Osteoporosis and inflammation. Arq. Bras. Endocrinol. 2010: 54 (2): 123–132.Shead E.F., Haworth C.S., Gunn E. et al. Osteoclastogenesis during infective exacerbations in patients with cystic fibrosis. Am. J. Respir. Crit. Care Med. 2006; 174: 306–311.Shead E.F., Haworth C.S., Gunn E. et al. Osteoclastogenesis during infective exacerbations in patients with cystic fibrosis. Am. J. Respir. Crit. Care Med. 2006; 174: 306–311.Shead E.F., Haworth C.S., Barker H. et al. Osteoclast function, bone turnover and inflammatory cytokines during infective exacerbations of cystic fibrosis. J. Cyst. Fibros. 2010; 9: 93–98.Shead E.F., Haworth C.S., Barker H. et al. Osteoclast function, bone turnover and inflammatory cytokines during infective exacerbations of cystic fibrosis. J. Cyst. Fibros. 2010; 9: 93–98.Ionescu A., Nixon L., Evans W. et al. Bone density, body composition, and inflammatory status in cystic fibrosis. Am. J. Respir. Crit. Care Med. 2000; 162 (3): 789–794.Ionescu A., Nixon L., Evans W. et al. Bone density, body composition, and inflammatory status in cystic fibrosis. Am. J. Respir. Crit. Care Med. 2000; 162 (3): 789–794.Aris R., Stephens A., Ontjes D. et al. Adverse alterations in bone metabolism are associated with lung infection in adults with cystic fibrosis. Am. J. Respir. Crit. Care Med. 2000; 162 (5): 1674–1678.Aris R., Stephens A., Ontjes D. et al. Adverse alterations in bone metabolism are associated with lung infection in adults with cystic fibrosis. Am. J. Respir. Crit. Care Med. 2000; 162 (5): 1674–1678.Haworth C., Selby P., Webb A. et al. Inflammatory related changes in bone mineral content in adults with cystic fibrosis. Thorax 2004; 59 (7): 613–617.Haworth C., Selby P., Webb A. et al. Inflammatory related changes in bone mineral content in adults with cystic fibrosis. Thorax 2004; 59 (7): 613–617.Boyle M.P., Noschese M.L., Watts S.L. et al. Failure of highdose ergocalciferol to correct vitamin D deficiency in adults with cystic fibrosis. Am. J. Respir. Crit. Care Med. 2005; 172 (2): 212–217.Boyle M.P., Noschese M.L., Watts S.L. et al. Failure of highdose ergocalciferol to correct vitamin D deficiency in adults with cystic fibrosis. Am. J. Respir. Crit. Care Med. 2005; 172 (2): 212–217.Rovner A.J., Stallings V.A., Schall J.A. et al. Vitamin D insufficiency in children, adolescents, and young adults with cystic fibrosis despite routine oral supplementation. Am. J. Clin. Nutr. 2007; 86 (6): 1694-1699.Rovner A.J., Stallings V.A., Schall J.A. et al. Vitamin D insufficiency in children, adolescents, and young adults with cystic fibrosis despite routine oral supplementation. Am. J. Clin. Nutr. 2007; 86 (6): 1694-1699.Hall W.B., Sparks A.A., Aris R.M. Vitamin D deficiency in cystic fibrosis. Int. J. Endocrinol. 2010: Article ID 218691.Hall W.B., Sparks A.A., Aris R.M. Vitamin D deficiency in cystic fibrosis. Int. J. Endocrinol. 2010: Article ID 218691.Cranney A., Horsley T., O'Donnell S. et al. Effectiveness and safety of vitamin D in relation to bone health. Evidence Report / Technology Assessment 2007; 158: 1–235.Cranney A., Horsley T., O'Donnell S. et al. Effectiveness and safety of vitamin D in relation to bone health. Evidence Report / Technology Assessment 2007; 158: 1–235.Wolfenden L.L., Judd S.E., Shah R. et al. Vitamin D and bone health in adults with cystic fibrosis. Clin. Endocrinol. 2008; 69: 374–381.Wolfenden L.L., Judd S.E., Shah R. et al. Vitamin D and bone health in adults with cystic fibrosis. Clin. Endocrinol. 2008; 69: 374–381.Gronowitz E., Larkö O., Gilljam M. et al. Ultraviolet B radiation improves serum levels of vitamin D in patients with cystic fibrosis. Acta Paediatr. 2005; 94 (5): 547–552. Баранова И.А. и др. Остеопороз у больных муковисцидозом: новая проблема и нерешенные вопросы 132 Пульмонология 4’2011Gronowitz E., Larkö O., Gilljam M. et al. Ultraviolet B radiation improves serum levels of vitamin D in patients with cystic fibrosis. Acta Paediatr. 2005; 94 (5): 547–552. Баранова И.А. и др. Остеопороз у больных муковисцидозом: новая проблема и нерешенные вопросы 132 Пульмонология 4’2011Khazai N.B., Judd S.E., Jeng L. et al. Treatment and prevention of vitamin D insufficiency in cystic fibrosis patients: comparative efficacy of ergocalciferol, cholecalciferol, and UV light. J. Clin. Endocrinol. 2009; 94: 2037–2043.Khazai N.B., Judd S.E., Jeng L. et al. Treatment and prevention of vitamin D insufficiency in cystic fibrosis patients: comparative efficacy of ergocalciferol, cholecalciferol, and UV light. J. Clin. Endocrinol. 2009; 94: 2037–2043.Conway S.P., Wolfe S.P., Brownlee K.G. et al. Vitamin K status among children with cystic fibrosis and its relationship to bone mineral density and bone turnover. Pediatrics 2005; 115: 1325–1331.Conway S.P., Wolfe S.P., Brownlee K.G. et al. Vitamin K status among children with cystic fibrosis and its relationship to bone mineral density and bone turnover. Pediatrics 2005; 115: 1325–1331.Fewtrell M.S., Benden C., Williams J.E. et al. Undercarboxylated osteocalcin and bone mass in 8–12 year old children with cystic fibrosis. J. Cyst. Fibros. 2008; 7: 307–312.Fewtrell M.S., Benden C., Williams J.E. et al. Undercarboxylated osteocalcin and bone mass in 8–12 year old children with cystic fibrosis. J. Cyst. Fibros. 2008; 7: 307–312.Grey V., Atkinson S., Drury D. et al. Prevalence of low bone mass and deficiencies of vitamins D and K in pediatric patients with cystic fibrosis from 3 Canadian centers. Pediatrics 2008; 122: 1014–1020.Grey V., Atkinson S., Drury D. et al. Prevalence of low bone mass and deficiencies of vitamins D and K in pediatric patients with cystic fibrosis from 3 Canadian centers. Pediatrics 2008; 122: 1014–1020.Nicolaidou P., Stavrinadis I., Loukou I. et al. The effect of vitamin K supplementation on biochemical markers of bone formation in children and adolescents with cystic fibrosis. Eur. J. Pediatr. 2006; 165: 540–545.Nicolaidou P., Stavrinadis I., Loukou I. et al. The effect of vitamin K supplementation on biochemical markers of bone formation in children and adolescents with cystic fibrosis. Eur. J. Pediatr. 2006; 165: 540–545.Drury D., Grey V.L., Ferland G. et al. Efficacy of high dose phylloquinone in correcting vitamin K deficiency in cystic fibrosis. J. Cyst. Fibros. 2008; 7: 457–459.Drury D., Grey V.L., Ferland G. et al. Efficacy of high dose phylloquinone in correcting vitamin K deficiency in cystic fibrosis. J. Cyst. Fibros. 2008; 7: 457–459.Aris R.M., Lester G.E., Renner J.B. et al. Efficacy of pamidronate for osteoporosis in patients with cystic fibrosis following lung transplantation. Am. J. Respir. Crit. Care Med. 2000; 162 (3, Pt 1): 941–946.Aris R.M., Lester G.E., Renner J.B. et al. Efficacy of pamidronate for osteoporosis in patients with cystic fibrosis following lung transplantation. Am. J. Respir. Crit. Care Med. 2000; 162 (3, Pt 1): 941–946.Aris R.M., Lester G.E., Caminiti M. et al. Efficacy of alendronate in adults with cystic fibrosis with low bone density. Am. J. Res. Crit. Care Med. 2004; 169 (1): 77–82.Aris R.M., Lester G.E., Caminiti M. et al. Efficacy of alendronate in adults with cystic fibrosis with low bone density. Am. J. Res. Crit. Care Med. 2004; 169 (1): 77–82.Boyle M.P., Lechtzin N., Watts S. Zoledronate therapy for decreased bone density in adults with cystic fibrosis [abstract]. Pediatr. Pulmonol. 2005; 40 (S28): 353.Boyle M.P., Lechtzin N., Watts S. Zoledronate therapy for decreased bone density in adults with cystic fibrosis [abstract]. Pediatr. Pulmonol. 2005; 40 (S28): 353.Chapman I., Greville H., Ebeling P.R. et al. Intravenous zoledronate improves bone density in adults with cystic fibrosis (CF). Clin. Endocrinol. 2009; 70: 838–846.Chapman I., Greville H., Ebeling P.R. et al. Intravenous zoledronate improves bone density in adults with cystic fibrosis (CF). Clin. Endocrinol. 2009; 70: 838–846.Haworth C.S., Selby P.L., Adams J.E. et al. Effect of intravenous pamidronate on bone mineral density in adults with cystic fibrosis. Thorax 2001; 56 (4): 314–316.Haworth C.S., Selby P.L., Adams J.E. et al. Effect of intravenous pamidronate on bone mineral density in adults with cystic fibrosis. Thorax 2001; 56 (4): 314–316.Papaioannou A., Kennedy C.C., Freitag A. et al. Alendronate once weekly for the prevention and treatment of bone loss in Canadian adult cystic fibrosis patients (CFOS Trial). Chest 2008; 134: 794–800.Papaioannou A., Kennedy C.C., Freitag A. et al. Alendronate once weekly for the prevention and treatment of bone loss in Canadian adult cystic fibrosis patients (CFOS Trial). Chest 2008; 134: 794–800.

The authors declare that there are no conflicts of interest present.